.png)
Workshop
Pre-reading
Tuesday 14 and Wednesday 15 October 2025
To ensure our workshops are as productive as possible, we've gathered pre-reading materials that offer practical insights into the issues at hand. Please take time to read the pre-reading for your allocated workshop beforehand, that way you'll be equipped with the knowledge and perspective needed to contribute meaningfully to our discussions.
Please note: Members of the media are not permitted to attend the Summit workshops.
Pru Etcheverry, ONZM
WORKSHOP 1 CHAIR
Director - Advocacy Answers
Georgie Hackett
WORKSHOP 1 CO-CHAIR
Director - Advocacy Answers
Workshop 1
Improving PHARMAC Processes & Policies: Towards a More Transparent, Timely, and Equitable System
This session run under Chatham House Rules explores opportunities to enhance Pharmac's decision-making, prioritisation, funding policies, and processes in the face of rising demand for innovative modern medicines. Stakeholders will examine current limitations and co-develop ideas to make Pharmac more responsive, transparent, and aligned with health equity goals. ​​​
​
​
PRE-READING LINKS - WORKSHOP 1
​
-
www.pharmac.govt.nz/assets/Uploads/Pharmac-Consumer-Engagement-Report-Final.pdf - Dame Kerry Prendergast Report , February 2025
-
Towards best practice in consumer involvement in decisions about funding medicines in New Zealand – Anne Single
-
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe – Tuba Saygin Avsar, Xiaozhe Yang, Paula Lorgelly
-
Co-design Project: Enhanced Consumer Engagement Process – The University of Melbourne
-
www.ohe.org/wp-content/uploads/2025/04/OHE-report-on-BRAVER_final.pdf - OHE 2025 BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
​
Tanya Baker
WORKSHOP 2 CHAIR
Head of Regulatory, Science & Technical Advice, Medicines New Zealand
Ruth Lucas
WORKSHOP 2 CO-CHAIR
Chair, NZ Association of
Clinical Research
Workshop 2
Unlocking Innovation: Building a Stronger Health Research & Clinical Trials Ecosystem in Aotearoa
This session focuses on strengthening New Zealand’s capacity to conduct world-class health research and clinical trials. It will explore system gaps, policy opportunities (e.g. horizon scanning), and how to better attract, support, and retain trials that align with national health priorities and benefit local populations — particularly underserved communities. ​​​​​​
PRE-READING LINKS - WORKSHOP 2
-
The Value of Clinical Research with Modern Medicines in New Zealand – NZIER
-
Enhancing Aotearoa New Zealand Clinical Trials – University of Auckland
-
Requirements for the National One Stop Shop, the National Clinical Trials Front Door and Core Elements of the National Site-Specific Assessment – Australian Government 
Christine Perrins
WORKSHOP 3 CHAIR
Advocacy Adviser, Cystic Fibrosis NZ
Dr Kerryn Symons
WORKSHOP 3 CO-CHAIR
Medical Director Roche NZ, Chair Medicines NZ Science & Innovation Working Group
Workshop 3
Legislation in Transition: Future-proofing and Optimising Medicines Regulations and Procurement in New Zealand
This session examines how New Zealand’s medicines access and funding framework is shifting assuming proposed changes to the Healthy Futures (Pae Ora) Amendment Bill, the Medicines Amendment Bill, the Gene Technology Bill, and the yet-to-be formulated Medical Products Bill. It will also explore how these pieces of legislation may impact both the medicines regulatory landscape and procurement systems including PHARMAC’s statutory functions. The workshop will determine if the medicines legislative changes also meet the needs of a modern, equitable, and responsive health system. ​​​​​​
PRE-READING LINKS - WORKSHOP 3
​
-
Medicines Act 1981
Health NZ overview: Click here
-
Medicines Amendment Bill 2025 Health NZ Overview - Click here
NZ Parliament Process - Click here
-
Medical Products Bill (Proposed) Health NZ Overview - Click here
Health NZ Documents - Click here
-
Pae Ora (Healthy Futures) Act 2022 Overview - Click here
-
Healthy Futures (Pae Ora) Amendment Bill 2025 Health NZ overview: Click here
NZ Parliament process - Click here
-
Gene Technology Bill 2024
MBIE Overview - Click here
NZ Parliament Process - Click here
Dr Stephen Child
WORKSHOP 4 CHAIR
​Chief Medical Officer, Southern Cross Health Society
_edited.jpg)
Sarah Hogan
WORKSHOP 4 CO-CHAIR
Deputy Chief Executive (Wellington) and Principal Economist NZIER
Workshop 4
Funding the Future: How will the Health System Sustainably Fund Modern Medicines?
This session tackles the difficult but necessary question: how can Aotearoa sustainably fund access to an increasing number of innovative medicines within a publicly funded health system? With constrained budgets and growing health inequities, participants will explore the pros, cons, and trade-offs of potential funding reforms — including tax policy, co-payments, private insurance, and new risk-sharing models.
​
​​​​​
PRE-READING LINKS - WORKSHOP 4
​
-
Treasury Long-term Fiscal Statement: The short version
(September 2025) - Click here
-
New Zealand’s health financing and expenditure: A comparative and historical review 2000-2023 (September 2025) - Click here
-
Summary of Managed Entry Agreements (MEA) for Pharmaceutical Procurement - Click here
"Attendee Disclaimer
By attending this Summit, you are acknowledging the following matters and rules applying to the conduct of the Summit, and agreeing to acting in accordance with them:
​
The attendees of the Event acknowledge that they understand the views and opinions expressed during the Event are those of each individual speaker/panellist and do not necessarily reflect the views or position of Medicines New Zealand or Patient Voice Aotearoa. The Summit has been organised to provide an opportunity for high-level discussion among a diverse range of local and international stakeholders in the health and medicine sector. Accordingly, the organisers have provided a platform for the speakers/panellists to express their own personal views and opinions.
During the Event the moderator will indicate when a session/panel event is subject to Chatham House Rule. Under the Chatham House Rule, participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed. The aim of Chatham House Rule is to bring people together, break down barriers, generate ideas and agree solutions. The attendees of the Summit agree and acknowledge that it is therefore of vital importance that what is said whilst Chatham House Rules apply, is not repeated or disclosed outside of the session."